Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

This is not true. Many companies that appeared

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
biosectinvestor Member Profile
Member Level 
Followed By 93
Posts 13,568
Boards Moderated 0
Alias Born 04/03/10
160x600 placeholder
CEO Presenting on the First Emerging Growth / Investors Hub Joint Conference on July 21 InvestorsHub NewsWire - 7/19/2021 7:00:00 AM
CEO Presenting on the Emerging Growth / Investors Hub Joint Conference Tomorrow.  Register Now InvestorsHub NewsWire - 7/6/2021 7:00:00 AM
Sino United (OTC Pink: SUIC) $200 Million Commitment, Signs with Suntech, the Largest Taiwan O2O Company. InvestorsHub NewsWire - 6/30/2021 7:30:00 AM
CEO Presenting on the First Emerging Growth / Investors Hub Joint Conference Tomorrow!  Register Now InvestorsHub NewsWire - 6/22/2021 7:00:00 AM
CEO's Presenting at Emerging Growth Conference Virtually This Week InvestorsHub NewsWire - 6/7/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/24/2021 4:35:22 PM
Northwest Bio gaining attention as investors await phase 3 GBM data Seeking Alpha - 5/24/2021 11:16:44 AM
CEO's Presenting at Emerging Growth Conference Virtually This Week InvestorsHub NewsWire - 5/24/2021 7:03:10 AM
IQST Signals BUY InvestorsHub NewsWire - 5/20/2021 9:43:19 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/17/2021 5:17:07 PM
CEO Presenting at Emerging Growth Conference Virtually This Week InvestorsHub NewsWire - 5/11/2021 7:00:00 AM
Nightfood, Inc. (OTCQB: NGTF) Joins Pepsico (NYSE: PEP), Unilever (NYSE: UL) and Bayer at Event InvestorsHub NewsWire - 5/5/2021 6:28:08 AM
Nightfood, Inc. (OTCQB: NGTF) in Walmart (NYSE: WMT) Coast to Coast over 1,000 Locations InvestorsHub NewsWire - 4/20/2021 7:09:50 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/31/2021 4:56:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/5/2021 8:32:22 AM
Emerging Growth Conference 2 Announced for March 3, 2021 Niche Companies in Technology, AR, eCommerce, Beverage and more .... InvestorsHub NewsWire - 3/1/2021 6:28:27 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/26/2021 4:55:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/19/2021 4:07:42 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 1/15/2021 7:21:09 AM
The FDA Calendar Review Dates Can Play a Big Role in Timing Your Trades, But Not the Way You May Think InvestorsHub NewsWire - 1/7/2021 8:00:00 AM
Biotech Companies; Recent Milestones and Potential Upside InvestorsHub NewsWire - 12/22/2020 8:05:00 AM
TNS is on the Hunt for the Next OTC Home Run Stock, Feature Report InvestorsHub NewsWire - 11/30/2020 8:20:00 AM
Immune Therapeutics, Inc. Spinoff Cytocom, Inc. Appoints BioPharm Industry Veteran as New Chief Operating Officer InvestorsHub NewsWire - 11/11/2020 9:11:00 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 11/10/2020 4:58:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/2/2020 2:16:52 PM
biosectinvestor Member Level  Wednesday, 06/16/21 07:32:41 PM
Re: FeMike post# 384869
Post # of 391153 
This is not true. Many companies that appeared to have been completely run, trying to do exactly the same thing, have failed catastrophically. Assuming this gets to validation, which depends on the technology, and the trial and the skill managing all of it, then the fact that they thought through the production issues ahead of time, in a manner that will further make the product affordable to produce and deliver, successfully, this will have been a huge accomplishment and success beyond what most other companies could dream of achieving.

We’re along for the ride. It is not meeting everyone’s timeline for “retirement”. I get it. There are opportunity costs for choosing this ride instead of another. But those choices are the shareholder’s choices. One could trade in and out quite profitably, and choose to bet on any number of other established biotechs with revenues and products. If investors are here and holding, it can’t be that they are incompetent, it might be that the entire process of validation is incredibly long and frustrating for breakthrough biomedical products like this, but it’s not that they are incompetent fools. If it fails even, personally, I would say it was a skillfully run effort, regardless of the complaints some might have.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences